Clinical Trial Update: NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Early-phase clinical trial evaluating neoadjuvant dose-dense MVAC with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma (infiltrating bladder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infiltrating Bladder Urothelial Carcinoma
• Muscle-invasive Urothelial Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Conditions: Infiltrating Bladder Urothelial Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN